Focus:
Comment
-
8 April 2020
Sanofi and partners’ success with repurposed antibodies for Covid-19 depend on recruiting less critically ill patients
Use of repurposed antibodies already approved for other indications to effectively treat Covid-19, like those from Sanofi in partnership with Regeneron, Roche and Eusa Pharma, require early intervention in the disease, even as...
-
2 April 2020
Mixed results from recently completed Covid-19 clinical trials
With the pandemic of Covid-19 affecting the way of life across the globe, companies continue to accelerate the clinical development of a vaccine or a therapeutic. The number of Covid-19...
-
30 March 2020
Influenza drug favipiravir is being tested to treat Covid-19
Treatment options for Covid-19 are urgently needed as the total number of confirmed cases globally rises to 550,000 on Friday and the US becomes the country with the most confirmed...
-
30 March 2020
Amid Covid-19 and trial delays, Apple and J&J’s CV study may hold advantage
Apple and Johnson & Johnson’s ongoing Heartline Study aims to evaluate changes in stroke risk and atrial fibrillation (AF) detection through the use of the Heartline Study’s app and the...
-
30 March 2020
Hydroxychloroquine trial to begin enrolling Covid-19 hospitalised patients next week
A placebo-controlled, randomised trial evaluating the use of hydroxychloroquine in patients who have tested positive for Covid-19 and are being admitted to the hospital for Covid illness will begin enrolment...
-
27 March 2020
A closer look at the first in human trial for a Covid-19 vaccine
With the accelerating global burden from the Covid-19 pandemic, researchers are rapidly searching for a viable vaccine to combat the global public health emergency.
-
25 March 2020
Trial delays in the time of Covid-19
Last week, GlobalData released an Analyst Briefing detailing the increase in overall clinical trial delays due to the global shift in focus to the Covid-19 pandemic (Clinical Trial Delays and...
-
22 March 2020
Covid-19: Experts say clinical trials may be affected from enrolment to data analysis
The ongoing Covid-19 pandemic is extensively impacting clinical trials irrespective of indication and not just in terms of recruitment and immediate patient care, but is also likely to affect data...
-
20 March 2020
The impact of the Covid-19 pandemic on clinical trials
The Covid-19 pandemic has the potential to disrupt new and ongoing clinical trials of various medical products. To help combat these complications, on March 18, the FDA issued guidance for...
-
19 March 2020
Late-stage failure of Imfinzi and Tremelimumab combination for bladder cancer and small-cell lung cancer
AstraZeneca’s combination of Imfinzi (durvalumab) and tremelimumab has faced multiple late-stage failures within the last couple of weeks.